Patents by Inventor John A. Zebala

John A. Zebala has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treating pain using desmetramadol
    Patent number: 11000488
    Abstract: There is disclosed a method for treating pain, comprising administering an analgesic oral dosage form comprising desmetramadol substantially free of tramadol.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: May 11, 2021
    Assignee: Syntrix Biosystems Inc.
    Inventor: John A. Zebala
  • Method for treating cancer using chemokine antagonists
    Patent number: 10993953
    Abstract: What is described is a method for treating cancer in a patient assaying levels of (a) CXCR1 and/or CXCR2 ligands or (b) myeloid derived suppressor cells (MDSCs) and/or neutrophils in the patient, and if the patient has increased levels of (a) or (b), then administering a therapeutically effective amount of a compound having a structure selected from the group consisting of formulas SX-517, SX-576, and SX-682
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: May 4, 2021
    Assignee: Syntrix Biosystems Inc.
    Inventors: John A. Zebala, Dean Y. Maeda, Aaron D. Schuler
  • TREATING PAIN USING DESMETRAMADOL
    Publication number: 20200297661
    Abstract: There is disclosed a method for treating pain, comprising administering an analgesic oral dosage form comprising desmetramadol substantially free of tramadol.
    Type: Application
    Filed: March 22, 2019
    Publication date: September 24, 2020
    Inventor: John A. Zebala
  • Compositions and methods for overcoming resistance to tramadol
    Patent number: 10702485
    Abstract: There is disclosed a composition for oral administration of O-desmethyltramadol. Compositions are also provided that are effective for overcoming resistance to tramadol in patients.
    Type: Grant
    Filed: July 8, 2012
    Date of Patent: July 7, 2020
    Assignee: Syntrix Biosystems Inc.
    Inventor: John A. Zebala
  • Method for treating cancer using chemokine antagonists
    Patent number: 10660909
    Abstract: What is described is a method for treating cancer in a patient in need of such treatment through the use of an antagonist to CXCR1 and/or CXCR2 receptors by administering a therapeutically effective amount of an antagonist of CXCR1 and/or CXCR2, or pharmaceutical compositions thereof, either alone as monotherapy, or in combination with at least one other anticancer therapy.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: May 26, 2020
    Assignee: Syntrix Biosystems Inc.
    Inventors: John A. Zebala, Dean Y. Maeda, Aaron D. Schuler
  • Method for treating cancer using dual antagonists of CXCR1 and CXCR2
    Patent number: 10561676
    Abstract: What is described is a method for treating cancer in a patient in need of such treatment through the use of a dual CXCR1/2 antagonist by administering a therapeutically effective amount of a dual CXCR1/2 antagonist, or pharmaceutical compositions thereof, either alone as monotherapy, or in combination with at least one other anticancer therapy.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: February 18, 2020
    Assignee: Syntrix Biosystems Inc.
    Inventor: John A. Zebala
  • METHOD FOR TREATING CANCER USING CHEMOKINE ANTAGONISTS
    Publication number: 20190381076
    Abstract: What is described is a method for treating cancer in a patient assaying levels of (a) CXCR1 and/or CXCR2 ligands or (b) myeloid derived suppressor cells (MDSCs) and/or neutrophils in the patient, and if the patient has increased levels of (a) or (b), then administering a therapeutically effective amount of a compound having a structure selected from the group consisting of formulas SX-517, SX-576, and SX-682
    Type: Application
    Filed: August 26, 2019
    Publication date: December 19, 2019
    Inventors: John A. Zebala, Dean Y. Maeda, Aaron D. Schuler
  • Use of thiopyrimidinecarboxamide for treating cancer
    Patent number: 10130645
    Abstract: There is disclosed is a method of treating disease using compound having formula SX-682 alone or in combination with an antineoplastic agent, microtubule affecting agents, antineoplastic agents, anti-angiogenesis agents, VEGF receptor kinase inhibitors, antibodies against the VEGF receptor, interferon, or radiation.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: November 20, 2018
    Assignee: Syntrix Biosystems, Inc.
    Inventors: John A. Zebala, Dean Y. Maeda, Aaron D. Schuler
  • METHOD FOR TREATING CANCER USING DUAL ANTAGONISTS OF CXCR1 AND CXCR2
    Publication number: 20180296580
    Abstract: What is described is a method for treating cancer in a patient in need of such treatment through the use of a dual CXCR1/2 antagonist by administering a therapeutically effective amount of a dual CXCR1/2 antagonist, or pharmaceutical compositions thereof, either alone as monotherapy, or in combination with at least one other anticancer therapy.
    Type: Application
    Filed: June 25, 2018
    Publication date: October 18, 2018
    Inventors: John A. Zebala, Dean Y. Maeda, Aaron D. Schuler
  • Method for treating cancer using chemokine antagonists
    Patent number: 10046002
    Abstract: What is described is a method for treating cancer in a patient in need of such treatment through the use of an antagonist to CXCR1 and/or CXCR2 receptors by administering a therapeutically effective amount of an antagonist of CXCR1 and/or CXCR2, or pharmaceutical compositions thereof, either alone as monotherapy, or in combination with at least one other anticancer therapy.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: August 14, 2018
    Assignee: SYNTRIX BIOSYSTEMS INC.
    Inventors: John A. Zebala, Dean Y. Maeda, Aaron D. Schuler
  • METHOD FOR TREATING CANCER USING CHEMOKINE ANTAGONISTS
    Publication number: 20180177808
    Abstract: What is described is a method for treating cancer in a patient in need of such treatment through the use of an antagonist to CXCR1 and/or CXCR2 receptors by administering a therapeutically effective amount of an antagonist of CXCR1 and/or CXCR2, or pharmaceutical compositions thereof, either alone as monotherapy, or in combination with at least one other anticancer therapy.
    Type: Application
    Filed: February 23, 2018
    Publication date: June 28, 2018
    Inventors: John A. Zebala, Dean Y. Maeda, Aaron D. Schuler
  • Aminopterin dosage forms
    Patent number: 9867828
    Abstract: Embodiments of the present invention provide dosage forms and methods for treating a patient with an inflammatory disorder with a therapeutically effective amount of aminopterin, or a pharmaceutically acceptable salt thereof, that achieve efficacy without concomitant toxicity. Within certain embodiments, the present invention provides a method for treating an inflammatory disorder in a patient with uninterrupted doses of aminopterin.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: January 16, 2018
    Assignee: Aminopterin LLC
    Inventor: John A. Zebala
  • METHODS FOR OVERCOMING RESISTANCE TO TRAMADOL
    Publication number: 20170319510
    Abstract: There is disclosed a method for treating disorders modulated by at least opiate receptor activity or monoamine activity, including acute and chronic pain, comprising administering a pharmaceutical formulation comprising O-desmethyltramadol. Methods are also provided that are effective for overcoming resistance to tramadol in patients.
    Type: Application
    Filed: July 27, 2017
    Publication date: November 9, 2017
    Inventor: John A. Zebala
  • COMPOSITIONS FOR OVERCOMING RESISTANCE TO TRAMADOL
    Publication number: 20170319511
    Abstract: Disclosed herein is a composition for oral administration of O-desmethyltramadol that is effective for overcoming resistance to tramadol in patients.
    Type: Application
    Filed: July 27, 2017
    Publication date: November 9, 2017
    Inventor: John A. Zebala
  • Methods for overcoming resistance to tramadol
    Patent number: 9808432
    Abstract: There is disclosed a method for treating disorders modulated by at least opiate receptor activity or monoamine activity, including acute and chronic pain, comprising administering a pharmaceutical formulation comprising O-desmethyltramadol. Methods are also provided that are effective for overcoming resistance to tramadol in patients.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: November 7, 2017
    Assignee: Syntrix Biosystems Inc.
    Inventor: John A. Zebala
  • USE OF THIOPYRIMIDINECARBOXAMIDE FOR TREATING CANCER
    Publication number: 20170281659
    Abstract: There is disclosed is a method of treating disease using compound having formula SX-682 alone or in combination with an antineoplastic agent, microtubule affecting agents, antineoplastic agents, anti-angiogenesis agents, VEGF receptor kinase inhibitors, antibodies against the VEGF receptor, interferon, or radiation.
    Type: Application
    Filed: June 20, 2017
    Publication date: October 5, 2017
    Inventors: John A. Zebala, Dean Y. Maeda, Aaron D. Schuler
  • Pyridinecarboxamides as CXCR2 modulators
    Patent number: RE47267
    Abstract: There is disclosed pyridine-and pyrimidinecarboxamide compounds useful as pharmaceutical agents, synthesis processes, and pharmaceutical compositions which include pyridine-and pyrimidinecarboxamides compounds. More specifically, there is disclosed a genus of CXCR2 inhibitor compounds that are useful for treating a variety of inflammatory and neoplastic disorders.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: March 5, 2019
    Assignee: Syntrix Biosystems, Inc.
    Inventors: Dean Y. Maeda, John A Zebala
  • Pyrimidinecarboxamides as CXCR2 modulators
    Patent number: RE47415
    Abstract: There is disclosed pyridine- and pyrimidinecarboxamide compounds useful as pharmaceutical agents, synthesis processes, and pharmaceutical compositions which include pyridine- and pyrimidinecarboxamides compounds. More specifically, there is disclosed a genus of CXCR2 inhibitor compounds that are useful for treating a variety of inflammatory and neoplastic disorders.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: June 4, 2019
    Assignee: Syntrix Biosystems, Inc.
    Inventors: Dean Y. Maeda, John A. Zebala
  • Aminopyridinecarboxamides as CXCR2 modulators
    Patent number: RE47740
    Abstract: There is disclosed aminopyridine- and aminopyrimidinecarboxamide aminopyridinecarboxamide compounds useful as pharmaceutical agents, synthesis processes, and pharmaceutical compositions which include aminopyridine- and aminopyrimidinecarboxamides aminopyridinecarboxamide compounds. More specifically, there is disclosed a genus of CXCR2 inhibitor compounds that are useful for treating a variety of inflammatory and neoplastic disorders.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: November 26, 2019
    Assignee: Syntrix Biosystems Inc.
    Inventors: Dean Y. Maeda, John A. Zebala, Aaron D. Schuler
  • Aminopyrimidinecarboxamides as CXCR2 modulators
    Patent number: RE48547
    Abstract: There are disclosed aminopyrimidinecarboxamide compounds useful as pharmaceutical agents, synthesis processes, and pharmaceutical compositions which include aminopyrimidinecarboxamides compounds. More specifically, there is disclosed a genus of CXCR2 inhibitor compounds that are useful for treating a variety of inflammatory and neoplastic disorders.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: May 11, 2021
    Assignee: Syntrix Biosystems Inc.
    Inventors: Dean Y. Maeda, John A. Zebala, Aaron D. Schuler